petosemtamab subcutaneous / Merus - LARVOL DELTA

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab (PRNewswire) - "Under the collaboration, Merus has licensed Halozyme's ENHANZE drug delivery technology, for the development and potential commercialization of subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody...Under the terms of the agreement, Merus will make an upfront payment to Halozyme, and potential future milestone payments related to commercial and sales attainment, if approved."

Licensing / partnership • Squamous Cell Carcinoma of Head and Neck